SBIR-STTR Award

Quantum Dots and Magnetic Nanoparticles for Ante-morem Diagnosis of Prion Infect
Award last edited on: 12/22/09

Sponsored Program
SBIR
Awarding Agency
NIH : NIAID
Total Award Amount
$270,509
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Zoraida P Aguilar

Company Information

Ocean Nanotech LLC (AKA: Ocean Nano Tech LLC)

7964 Arjons Drive Suite G
San Diego, CA 92126
   (858) 689-8808
   info@oceannanotech.com
   www.oceannanotech.com
Location: Single
Congr. District: 51
County: San Diego

Phase I

Contract Number: 1R43AI084299-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2009
Phase I Amount
$270,509
NIH Phase I Quantum dots and Magnetic nano-particles for Ante-mortem Diagnostics of m Prion Infection Ocean Nano Tech proposes to develop a portable, rapid, sensitive, high throughput, inexpensive, and easy to use system for the ante-mortem diagnosis of prion infection using high emission intensity quantum dots and magnetic nanoparticles in a disposable lab-on-a-chip (dLOAC) format. The proposed system consists of a fully automated equipment consisting of a miniaturized fluorimeter that uses dLOAC and miniaturized pumps for automated delivery of reagents. The dLOAC is configured for ante-mortem diagnosis of 1 x 10-15 molar (possibly 1 x 10-18molar) concentrations of PrPSc in a rapid assay d 60 min, high throughput allowing > 50 samples/h per instrument, high sensitivity with > 95% reliability (eliminating false positives and false negatives), and minimizing the hazard of handling infected biological fluids. This system will diagnose prion infection before the appearance of clinical symptoms and is anticipated to replace post mortem diagnostic methods that are useful only in the advanced stage of the disease that is always fatal. The proposed system will lead to products used for: 1) diagnosis of PrPSc levels in asymptomatic cows (and for humans with additional development), 2) monitor PrPSc levels in donated blood (with additional development on the dLOAC and using the same instrument), 3) monitor PrPSc levels in beef and cow parts at slaughter houses to eliminate contaminated meat and meat products from entering the market, 4) monitor PrPSc levels in industrial products that use cow-derived raw materials, 5) monitor drug and vaccine development, and 6) monitor the efficacy of drugs, vaccine, and therapeutic agents during medication. In addition, the products are also usable for post-mortem diagnosis. These products have enormous commercial and societal impact. Ante-mortem diagnosis in beef that brings >$ 9 billion income will protect beef industry in the US. With additional development, the instruments and dLOAC will have use in stationary or mobile clinics or hospitals as diagnostic tool for early detection, ante- and post-mortem detection of prion disease in humans.

Public Health Relevance:
The products resulting from this project for ante-mortem detection of prion infection have various urgent commercial applications with enormous societal impact. Its applications include the >$10 billion beef industry in the US and worldwide, monitoring of donated blood amounting to 12-14 million units of whole blood collected annually in the US and 80 million units worldwide, and detection of prions in tissues for transplant, for grafting, and for use as raw materials for various food, cosmetic, and medical products because of the fatal nature of the infection. The products can also be used to monitor drug and vaccine development and to monitor the efficacy of drugs, vaccine, or other therapeutic agents during medication.

Public Health Relevance Statement:
NIH Prion Project Narrative The products resulting from this project for ante-mortem detection of prion infection have various urgent commercial applications with enormous societal impact. Its applications include the >$10 billion beef industry in the US and worldwide, monitoring of donated blood amounting to 12-14 million units of whole blood collected annually in the US and 80 million units worldwide, and detection of prions in tissues for transplant, for grafting, and for use as raw materials for various food, cosmetic, and medical products because of the fatal nature of the infection. The products can also be used to monitor drug and vaccine development and to monitor the efficacy of drugs, vaccine, or other therapeutic agents during medication.

Project Terms:
1H-Thieno(3,4-d)imidazole-4-pentanoic acid, hexahydro-2-oxo-, (3aS-(3aalpha,4beta,6aalpha))-; Abattoirs; Absorption; Achievement; Achievement Attainment; Acute; Agriculture; Amines; Animals; Antibodies; Appearance; Aspiration, Respiratory; Assay; BSL-2 facility; BSL2 facility; Bioassay; Biologic Assays; Biological; Biological Assay; Biological Function; Biological Process; Biotin; Blood; Blood Serum; Blotting, Western; Body Tissues; Bovine Species; Brain; Breathing; Build-it; CDC; Cattle; Cell Communication and Signaling; Cell Signaling; Cell/Tissue, Immunohistochemistry; Centers for Disease Control; Centers for Disease Control (U.S.); Centers for Disease Control and Prevention; Centers for Disease Control and Prevention (U.S.); Clinical; Clinical Trials, Phase I; Clinics and Hospitals; Clinics or Hospitals; Collaborations; Color; Coloring Agents; Cosmetics; Data; Detection; Development; Device or Instrument Development; Devices; Diagnosis; Diagnosis, clinical; Diagnostic; Diagnostic Method; Diagnostic Procedure; Diagnostic Technique; Disease; Disorder; Drug Monitoring; Drugs; Dyes; Early Diagnosis; Early-Stage Clinical Trials; Economic Income; Economical Income; Encephalon; Encephalons; Endopeptidase K; Equipment; Exhibits; Eye; Eyeball; Farm; Farm Animal; Farming environment; Figs; Figs - dietary; Fluorescence; Food; Foundations; G-Proteins; G-substrate; GTP-Binding Proteins; GTP-Regulatory Proteins; Generations; Goals; Graft Material; Guanine Nucleotide Coupling Protein; Guanine Nucleotide Regulatory Proteins; Harvest; Heating; High Throughput Assay; Hour; Housing; Human; Human Resources; Human, General; Hydrogen Oxide; Hypochlorous acid, sodium salt; IHC; Image; Immobilization; Immunohistochemistry; Immunohistochemistry Staining Method; Incineration; Income; Industrial Product; Industry; Infection; Ingestion; Inhalation; Inhaling; Injection of therapeutic agent; Injections; Inspiration, Respiratory; Intracellular Communication and Signaling; Lab On a Chip; Label; Lead; Life; Liquid substance; Livestock; Livestocks; Magnetism; Man (Taxonomy); Man, Modern; Manpower; Marketing; Meat; Meat Products; Medical; Medication; Membrane; Methods; Modeling; Monitor; NIH; Nanoscale Science; Nanotechnology; National Institutes of Health; National Institutes of Health (U.S.); Nature; Nervous System, Brain; Neurologic Dysfunctions; Oceans; Optics; Organism; Ovis; Patients; Pb element; Pharmaceutic Preparations; Pharmaceutical Preparations; Phase; Phase 1 Clinical Trials; Phase I Clinical Trials; Phase I Study; Photobleaching; Physiologic; Physiological; Polymers; PrP 33-35; PrP Proteins; PrP Sc; PrP(Sc); PrP-res; PrPSc; PrPSc Proteins; Preparation; Prion Disease Pathway; Prion Diseases; Prion Protein Diseases; Prion Proteins; Prion-Induced Disorder; Prions; Process; Process of absorption; Production; Programs (PT); Programs [Publication Type]; Property; Property, LOINC Axis 2; Protease K; Proteinase K; Pump; Q-Dot; Quantum Dots; Reading; Reagent; Reliability of Results; Research; Resistance; Reticuloendothelial System, Blood; Rida; Running; Sampling; Scrapie; Scrapie PrP; Scrapie PrP 33-35; Series; Serum; Sheep; Signal Transduction; Signal Transduction Systems; Signaling; Site; Skin; Slaughterhouses; Sodium Hypochlorite; Sodium Hypochlorite (Solution); Solutions; Source; South Dakota; Sp 33-35; Spongiform Encephalopathies, Transmissible; Staging; Strepavidin; Streptavidin; Surface; Swab; Symptoms; Syringes; System; System, LOINC Axis 4; Technology; Testing; Therapeutic; Therapeutic Agents; Thermal Destruction; Time; Tissues; Training; Transmissible Dementias; Transplanted tissue; Tritirachium Alkaline Proteinase; United States Centers for Disease Control; United States Centers for Disease Control and Prevention; United States National Institutes of Health; Universities; Urinary System, Urine; Urine; Vaccines; Vitamin H; WHBLOOD; Water; Western Blotting; Western Blottings; Western Immunoblotting; Whole Blood; Work; absorption; agricultural; antibody conjugate; beef; biological signal transduction; biomarker; biosafety level 2 facility; bovid; bovine; cerebellum protein substrate for cGMP dependent protein kinase; clinical Diagnosis; coenzyme R; colcothar; commercial application; cosmetic product; cost; cow; design; designing; device development; disease-associated PrP; disease/disorder; drug efficacy; drug/agent; early detection; efficacy testing; experiment; experimental research; experimental study; ferric oxide; fluid; functional group; hazard; heavy metal Pb; heavy metal lead; high throughput analysis; high throughput screening; imaging; immobilization of body part; improved; in vivo; inspiration; instrument; instrument development; iron oxide; light emission; liquid; living system; magnetic; magnetic beads; membrane structure; micro-total analysis system; miniaturize; mu-TAS; nano particle; nano scale Science; nano sized; nano tech; nano technology; nanoparticle; nanosized; nanotech; neurological dysfunction; orthopedic freezing; particle; personnel; phase 1 study; phase 1 trial; phase I trial; programs; protein G; protein blotting; protocol, phase I; prototype; public health relevance; quantum; rapid detection; red iron oxide; research study; resistant; seal; spongiform degeneration; spongiform encephalopathy; success; tool; user-friendly; vaccine development; wasting

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----